Sage rebounds after next-gen postpartum depression readout

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $41.62 (43%) to $139.13 on Jan. 7 after it said SAGE-217 met the primary endpoint in the Phase III ROBIN trial to treat women with severe postpartum depression. The move

Read the full 355 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE